Biotechnology
Technology
Health

Pacific Biosciences

$7.23
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.11 (-1.50%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell PACB and other stocks, options, ETFs, and crypto commission-free!

About

Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. Its products and services include PacBio sequel system, consumables, analytical software, and single molecule real-time (SMRT) compatible products. Read More It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

Employees
401
Headquarters
Menlo Park, California
Founded
2000
Market Cap
1.10B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.99M
High Today
$7.36
Low Today
$7.20
Open Price
$7.33
Volume
608.62K
52 Week High
$7.84
52 Week Low
$2.44

Collections

Biotechnology
Technology
Health
Software Service
US
North America

News

NasdaqMay 7

Pacific Biosciences (PACB) Incurs Loss in Q1, Revenues Fall

Pacific Biosciences of California PACB incurred first-quarter 2019 adjusted loss of 20 cents per share, wider than the Zacks Consensus Estimate of a loss of 17 cents.

36
Seeking AlphaMay 3

Pacific Biosciences of California misses by $0.05, misses on revenue

Pacific Biosciences of California (NASDAQ:PACB): Q1 GAAP EPS of -$0.20 misses by $0.05. Revenue of $16.43M (-15.1% Y/Y) misses by $4.88M . Press Release...

17
NasdaqMay 3

Pacific Biosciences of California, Inc. Announces First Quarter 2019 Financial Results

MENLO PARK, Calif., May 03, 2019 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced financial results for its first quarter ended March 31, 2019, as attached. During the first quarter of 2019, the Company announced that it commenced its Early Access Program of the Sequel II System and the SMRT Cell 8M chip with five early access sites. All five early access sites successfully tested the new Sequel II System across a wide variety of customer samples with positive...

0

Earnings

-$0.21
-$0.18
-$0.16
-$0.13
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.15 per share
Actual
-$0.20 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.